Prilenia Therapeutics B.V. and Ferrer announced that the US Food and Drug Administration (FDA) has cleared the start of the pivotal, 500-patient, r...
Enko Chem, Inc. announced that a novel fungicide class of chemistry developed in collaboration with Syngenta Crop Protection has advanced to field ...
Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced the s...
Mindpeak, a global pioneer in AI-powered pathology solutions, is thrilled to announce that it has been granted its first patent, covering a groundb...
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology ta...
SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic...
Quotient Sciences, a leading global drug development, research and manufacturing accelerator, and Intrepid Labs, the AI leader in pharmaceutical formulat...
BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involve...
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to o...
Taiho Oncology Europe GmbH announced the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibi...
MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT0553...
Dosing of first MAD cohort in Phase 1 trial of O3R-5671 complete with no drug related adverse events Pharmacokinetic profile demonstrates long half-life...
VANUDIS, a biotechnology startup developing the next generation of antibody-based therapeutics, has implemented Cenevo’s Labguru solution to scale ...
Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, announced that the first patient...
© 2026 Biopharma Boardroom. All Rights Reserved.
